United Therapeutics (UTHR) Research & Development (2009 - 2026)

United Therapeutics has disclosed Research & Development across 18 years of filings, most recently posting $138.2 million for Q1 2026.

• Research & Development for Q1 2026 came in at $138.2 million, down 7.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $539.2 million (up 2.53% YoY), and the FY2025 annual result was $550.0 million, up 14.35% from the prior year.
• Research & Development came in at $138.2 million for Q1 2026 at United Therapeutics, down from $139.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $151.4 million in Q4 2023 to a low of $66.1 million in Q3 2022.
• The 5-year median for Research & Development is $104.1 million (2024), against an average of $111.8 million.
• Across the five-year window, Research & Development sank 77.28% in 2022 and jumped 61.24% in 2023, its largest moves.
• United Therapeutics' Research & Development stood at $93.9 million in 2022, then jumped by 61.24% to $151.4 million in 2023, then retreated by 11.62% to $133.8 million in 2024, then advanced by 4.26% to $139.5 million in 2025, then declined by 0.93% to $138.2 million in 2026.
• The last three Research & Development figures came in at $138.2 million (Q1 2026), $139.5 million (Q4 2025), and $127.5 million (Q3 2025), per Business Quant data.